Qualigen Therapeutics Partners with TD2 for Phase I Clinical Development of QN-302 for the Treatment of Advanced or Metastatic Solid Tumors

Qualigen Therapeutics, Inc. announced it is partnering with Translational Drug Development (TD2) as the contract research organization to conduct the Phase I clinical development of lead drug candidate QN-302, a small molecule G-Quadruplex-selective transcription inhibitor, for the treatment of advanced or metastatic solid tumors.